Sunny Jandyal,Jyoti Bajpai*
Ovarian function suppression (OFS) an old endocrine therapy has been tested in premenopausal women with early breast cancer (EBC) but not widely accepted in modern practice. The question is re-addressed in recent big trials, however the big dilemma doesn't resolved. This perspective touch upon the ancient as well as current evidence of OFS in these young early breast cancer women and try to enlighten the readers further on this controversial topic wherein there is lots of light but little illumination.
この記事をシェアする
English 
Spanish 
Chinese 
Russian 
German 
French 
Portuguese 
Hindi 